FEATURES AND CLINICAL BENEFITS
| FEATURES |
BENEFITS |
Once in contact with wound exudate (fluid in the wound), the TLC-NOSF technology of UrgoStart® Plus Absorb gelifies, which helps to:
|
- Limit the effect of the enzymes called matrix metalloproteinases (MMPs), excess of which in chronic wounds delays wound healing.
- Maintain a moist environment necessary for wound healing.
|
The polyacrylate fibres:
|
- Promote wound desloughing by trapping fibrin (yellow slough on the wound bed).
- Help stop minor bleeding (haemostatic properties evaluated in vitro).
|
UrgoStart® Plus Absorb:
- is suitable for covering also the periwound skin even when the skin is weakened.
- is easy to apply.
- is flexible (adapts to the body area to which it is applied) and comfortable.
- is made of a waterproof backing not permeable to bacteria from the outside environment.
- is vapour permeable.
- is atraumatic for the wound and the periwound skin when it is removed.
INDICATIONS
UrgoStart® Plus Absorb is indicated for covering and treating the following skin wounds
- Leg ulcers
- Diabetic foot ulcers
- Pressure ulcers (bedsores)
- Other long-lasting or recurrent wounds or wounds at risk of long-lasting
UrgoStart® Plus Absorb is intended to be used for all healing phases: it is suitable for application to wounds covered with fibrin (yellowish slough on the wound bed) and to wounds with granulation tissue (red budding tissue on the wound).
UrgoStart® Plus Absorb must be secured with a dressing securement system (for example medical tape, flat, tubular mesh, or adhesive dressing).
CONTRAINDICATIONS
- Mucous membrane wounds
- Malignant wounds
- Fistula wounds
- Epidermolysis bullosa wounds
- Necrotic wounds (wounds covered with black dead tissue, eschars).
- Haemorrhagic wounds: UrgoStart® Plus Absorb can be used to help stop minor bleeding but should not be used as a surgical sponge.
- Known hypersensitivity of the patient to one of the TLC or TLC-NOSF dressings, or to carboxymethylcellulose (CMC).
PRECAUTIONS
In the event of signs or symptoms of infection before or after starting treatment with UrgoStart® Plus Absorb, such as erythema (redness of the skin around the wound), oedema (swelling), heat or pain in the wound area, fever, enlargement of the wound, odour from the wound, or profuse exudate (that is, a large amount of fluid in the wound), consult a healthcare professional for appropriate treatment.
In the event of overgranulation (excessive raised formation of red budding tissue on the wound) before or after starting treatment with UrgoStart® Plus Absorb it must be reported to a healthcare professional for appropriate care.
Warnings
- Keep the pouches of UrgoStart® Plus Absorb in their box until use (does not apply to large capacity packaging intended for hospitals)
- Do not use a previously used dressing
- Do not re-sterilize
- Do not use beyond expiration date
- The use of a dressing that is in non-sterile condition, re-sterilized, or beyond expiration date, does not guarantee performance of UrgoStart® Plus Absorb and exposes the patient to the risk of infection
DIRECTIONS FOR USE
- Please adhere to wound bed preparation protocols prior to applying UrgoStart® Plus Absorb
- Can be commenced on wound with 100% slough through to complete healing
- Remove the plastic backing of UrgoStart® Plus Absorb and apply the adhesive side down on the wound
- Due to it’s non-adherent properties, allow a 1-2cm overlap onto the surrounding skin to minimise dressing movement
- Use an uncoated, absorbent secondary dressing suitable for the wound type and location
- Can be left in place for up to 7 days, however, follow hospital protocol and clinical judgement of the patient and wound
- Slightly increased levels of exudate are normal during the initial phase of wound management
- The recommended minimum treatment duration is ~4 weeks
